Posts Tagged ‘Gene’

New Gene Test Provides Approximate Survival Rates for Mesothelioma Patients

New Gene Test Provides Approximate Survival Rates for Mesothelioma Patients

According to a study published in the May 6 Journal of the National Cancer Institute(JNCI), scientists have recently devised a test that can accurately predict which mesothelioma patients have the best chance for survival. The test is also useful for identifying which patients would be the best candidates for surgery, another treatment option for mesothelioma cancer.

The test works by identifying the ratios of four genes present in tissue samples of mesothelioma cancer patients and comparing them with samples of tissue from patients who have survived mesothelioma cancer for an extended period of time. The gene test proved to provide consistent and easily repeatable results across different research campuses. Despite different technicians using different instruments in different laboratories, the test showed a high efficacy rate.

The test was devised by Dr. Raphael Bueno, the Associate Chief in the Division of Thoracic Surgery and Director of the Thoracic Surgery Residency Program at Brigham and Women’s Hospital in Boston, Massachusetts. Previously, predicting a patient’s prognosis was an invasive process; according to Dr. Bueno, major surgery was required to adequately predict the outcome. In the interest of creating a more accessible, less invasive, and accurately informative test, Dr. Bueno and his team looked to preexisting cancer tests. Specifically, the team looked at two gene-based testing methods that have been used in predicting breast cancer recurrence. Though this technology has not been widely used due to heavy logistical requirements, the inspiration provided enough incentive to help Dr. Bueno and his team develop what could be one of the biggest steps forward in accurate mesothelioma diagnosis in recent years.

The study announced in the JNCI was to determine how accurately the test predicted the survival rates of patients. Researchers examined samples of tissue from 120 mesothelioma patients and followed their cases until 2007 or until their death. Using the gene ratio test, researchers categorized the participants in two groups: a good outcome group, and a poor outcome group. On average, the poor outcome group survived 9.5 months; the good outcome group survived 16.8 months, almost double the rate of survival.

Since this test is so revealing about the survival rates of patients, it provides an opportunity for families and individuals to choose the best treatment option for mesothelioma cancer. Patients with good gene ratio test results could be more likely to benefit from surgery, while those in the lower survival rate group seek the best supportive care available.

Mesothelioma is often a very debilitating condition that may require large amounts of physical therapy and treatment options as well as require thousands of dollars in medical costs. It is common for many patients to discuss a mesothelioma lawsuit with an experienced personal injury attorney.

By contacting a mesothelioma lawyer, a patient is increasing their chances of receiving monetary funds as a compensation for the damages endured because of mesothelioma cancer. Additionally, a mesothelioma lawsuit may also result in the reimbursement of expensive medical bills as well as open the door for patients to receive costly medical care that they may have otherwise been able to afford or receive.

For more information on mesothelioma, visit http://mesothelioma.legalview.com for access to a wide variety or resources, including a mesothelioma attorney, a
mesothelioma lawsuit
, and a mesothelioma lawyer. LegalView also provides access to a construction accident lawyer as well.


Article from articlesbase.com

Find More Lawsuit Mesothelioma Articles

Examining Malignant Mesothelioma for Gene Mutations

Examining Malignant Mesothelioma for Gene Mutations

An interesting study is called, “Diagnosis of diffuse malignant mesothelioma: experience of a US/Canadian Mesothelioma Panel.” By McCaughey WT, Colby TV, Battifora H, Churg A, Corson JM, Greenberg SD, Grimes MM, Hammar S, Roggli VL, Unni KK. – Mod Pathol. 1991 May;4(3):342-53.  Here is an excerpt: “Abstract – The experience of the US/Canadian Mesothelioma Panel with its first 200 cases is reviewed. The light microscopic diagnosis, histochemical findings, immunohistochemical findings, and electron microscopic features of malignant mesotheliomas are reviewed in the context of differential diagnosis. Reasons for referral of case material to the panel and lessons from follow-up of difficult and controversial cases are reported. Recommendations to general pathologists are made regarding evaluation and review of possible mesotheliomas.”

An interesting study is called, “Molecular biology studies on mesothelioma tumor samples: preliminary data on H-ras, p21, and SV40.” By Cristaudo A, Vivaldi A, Sensales G, Guglielmi G, Ciancia E, Elisei R, Ottenga F – Institute of Endocrinology, University of Pisa, Italy. J Environ Pathol Toxicol Oncol. 1995;14(1):29-34.  Here is an excerpt: “Abstract – The ras gene is one of the oncogenes most commonly detected in human cancers; this protooncogene is converted to active oncogene by point mutations occurring at either codon 12, 13, or 61. SV40 is a DNA-transforming simian virus, a 105 bp sequence of which has been shown recently to be present in a significant fraction of human mesothelioma cells. Eleven human malignant mesotheliomas were examined for H-ras gene mutations at codon 12, 13, and 61 and for the presence of SV40-like sequences. DNA prepared from formalin-fixed and paraffin-embedded tissue was amplified by means of PCR and analyzed using designed restriction fragment length polymorphism. No mutation with respect to H-ras was found in any tumor sample, but the majority of mesothelioma cells contained SV40-like sequences.”

Another interesting study is called, “Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.” By Ordóñez NG – University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.  Hum Pathol. 1998 Feb;29(2):166-9.  Here is an excerpt: “Abstract – MOC-31 is a monoclonal antibody that has recently become commercially available that recognizes an epithelial-associated, transmembrane glycoprotein often expressed in epithelial tumors. Although some authors have indicated that MOC-31 immunostaining can assist in distinguishing epithelial mesotheliomas from metastatic adenocarcinomas to the pleura, others have concluded that this marker has no value in separating these conditions. To determine whether MOC-31 immunostaining can assist in discriminating epithelial pleural mesothelioma from lung adenocarcinoma or from other carcinomas metastatic to the pleura, 38 epithelial pleural mesotheliomas, 40 pulmonary adenocarcinomas, 55 nonpulmonary adenocarcinomas, six squamous cell carcinomas of the lung (SCCLs), three small-cell lung carcinomas (SCLCs), 19 bronchial carcinoids (BCs), and 15 transitional cell carcinomas (TCCs) were studied. Reactivity was obtained in two (5%) of the mesotheliomas, in all 40 (100%) pulmonary adenocarcinomas, in 45 (82%) nonpulmonary adenocarcinomas, in six (100%) SCCLs, three (100%) SCLCs, 15 (83%) BCs, and 10 (67%) TCCs. The staining in the two positive mesotheliomas was restricted to a few cells, in contrast to the pulmonary adenocarcinomas and most of the other carcinomas where it was often strong and diffuse. It is concluded that MOC-31 can be useful in separating epithelial pleural mesothelioma from pulmonary adenocarcinoma or from other epithelial malignancies involving the pleura.”

We all owe a debt of gratitude to these fine researchers.  If you found any of these excerpts interesting, please read the studies in their entirety.

Monty Wrobleski is the author of this article.  For more information please click on the following links

Depuy Hip Recall Attorney

Depuy Hip Recall Lawyer

Depuy Hip Recall Lawyer

 


Article from articlesbase.com

Categories